Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,599.00
Bid: 1,594.50
Ask: 1,595.50
Change: -19.00 (-1.17%)
Spread: 1.00 (0.063%)
Open: 1,608.00
High: 1,615.00
Low: 1,575.00
Prev. Close: 1,618.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MARKET PULSE-Apple, Sony, Oncolytics, Biodel, BlackBerry

Mon, 09th Sep 2013 12:15

(For more market insights, including options activity, click on ; for the Day Ahead newsletter http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s)

Sept. 9 (Reuters) - Some U.S. stocks to watch on Monday:

FUTURES RISE AFTER CHINA DATA; SYRIA CONCERNS REMAIN

U.S. stock index futures advanced in the wake of upbeateconomic data from China, though concerns remained about apotential strike against Syria. S&P 500 futures rose 3.3points and were above fair value, a formula that evaluatespricing by taking into account interest rates, dividends andtime to expiration on the contract. Dow Jones industrial averagefutures gained 25 points, and Nasdaq 100 futures added 11.75 points.

** APPLE INC, Friday close $498.22, up 1.2 pctpremarket

Brokerage FBN Securities raised its price target on thecompany's stock to $600 from $575 in anticipation of Applemaking an announcement of its iPhone 5S and iPhone 5C onTuesday. The brokerage said it expected the phones to startshipping on Sept. 20. FBN sees the iPhone 5C as an opportunityfor Apple to be successful in China.

** ONCOLYTICS BIOTECH INC, Friday close $2.65, up17 pct premarket

The company said its cancer drug, Reolysin, reduced the sizeof tumors in 92 percent of lung cancer patients in a mid-stagetrial.

** BIODEL INC, Friday close $5.03, up 12 pctpremarket

The pharmaceutical company said on Sunday that preliminarydata showed its fast-acting regular human insulin BIOD-123 metits goal in a mid-stage trial.

** ISIS PHARMACEUTICALS INC, Friday close $27.92,up 7 pct premarket

Biogen Idec Inc has agreed to pay another $100million upfront to the drugmaker as a part of a broadcollaboration to develop new medicines for neurologicaldisorders, the companies said.

** BLACKBERRY LTD, Friday close $10.84, up 4.3 pctpremarket

The company's largest shareholder, Prem Watsa, has assembledbillions in backing from Canada's biggest pension funds for abid, The Sunday Times reported on Sunday. (http://link.reuters.com/caz82v)

Watsa is the founder and chairman of Fairfax FinancialHoldings Ltd that holds about 10 percent stake in the company.

** SMITHFIELD FOODS INC, Friday close $33.92, up 2pct after market

The U.S. Committee on Foreign Investment has cleared the wayfor Shuanghui International Holdings Ltd's proposed $4.7 billionacquisition of Smithfield Foods, the companiessaid.

** JOHNSON & JOHNSON, Friday close $87.16, up 1 pctpremarket

The company has launched a sale process for its OrthoClinical Diagnostics unit, which makes blood screening equipmentand laboratory blood tests and could fetch around $5 billion.J&J has asked JPMorgan Chase & Co to run the sale and ispreparing to send detailed financial information in coming weeksto potential buyers.

** VODAFONE PLC, Friday close $32.89

The company may fail to reach the 75 percent threshold ofacceptances from shareholders needed to clinch Germany's largestcable operator Kabel Deutschland, the Financial Timessaid. Vodafone agreed a 7.7 billion euro ($10.13 billion) offerfor Kabel Deutschland in June, a near 40 percent premium toKabel's share price before its interest first emerged.

** SONY CORP, Friday close $21.02, down 2 pct aftermarket

The electronics maker announced the Japanese release of itsPlayStation 4 on Monday as the company braces for a gamingconsole war with Microsoft Corp that could make orbreak the Japanese firm's struggle to return to profit.

** GLAXOSMITHKLINE PLC, Friday close $51.67

Japan's Suntory Beverage & Food Ltd is to buyGlaxoSmithKline's Lucozade and Ribena brands for 1.35 billionpounds ($2.11 billion) to expand into new markets.

** GOOGLE INC, Friday close $879.58

The U.S. government tapped into computer networks ofcompanies including Google and Brazilian state-run oil firmPetroleo Brasileiro SA, according to leaked U.S.documents aired by Globo, Brazil's biggest television network.

** TIME WARNER INC, Friday close $61.45

The entertainment company is planning to transfer its U.S.retirees from company-sponsored health plans and move them toprivate insurance exchanges. According to an August memoobtained by Reuters, the media company will make allocations toa Health Reimbursement Arrangement account for retirees to usetowards the purchase of coverage on an exchange. Previously,Time Warner provided an indirect subsidy through a supplementaryMedicare program. (Compiled by Varun Aggarwal; Editing by Kirti Pandey)

More News
17 Jan 2024 07:46

LONDON BRIEFING: UK inflation surprises as unexpectedly rises to 4.0%

(Alliance News) - Stocks in London are called to open lower on Wednesday, following some hotter-than-expected consumer price data from the UK.

Read more
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more
9 Jan 2024 07:16

GSK buys respiratory drug maker Aiolos for $1bn

(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

Read more
8 Jan 2024 23:39

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 23:00

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.